LakeShore Biopharma Warrants
LSBPW
LSBPW was delisted on the 19th of September, 2025.
3 hedge funds and large institutions have $32 invested in LakeShore Biopharma Warrants in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 16 closing their positions.
2.7% less ownership
Funds ownership: 2.7% → 0% (-2.7%)
84% less funds holding
Funds holding: 19 → 3 (-16)
100% less capital invested
Capital invested by funds: $331K → $32 (-$331K)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 16
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Athos Capital
Hong Kong
|
-$132K |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
-$42K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$41.8K |
| 4 |
VAM
Valliance Asset Management
Central,
Hong Kong
|
-$29.9K |
| 5 |
Jane Street
New York
|
-$19.9K |
LSBPW Hedge Fund Activity: Q3 2025 in Review
3 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q3 2025, worth a combined $32 — down 100% from $331K a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LSBPW and 0 opened new positions — a net loss of 16 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Athos Capital, exiting entirely with an estimated $132K sold.
- 3 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q3 2025, down from 19 in Q2 2025.
- Funds reported $32 of LakeShore Biopharma Warrants stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new LakeShore Biopharma Warrants positions in Q3 2025 and 16 closed out, a net change of -16 holders.
- The largest LakeShore Biopharma Warrants seller in Q3 2025 was Athos Capital, an estimated $132K sold.
Based on aggregated 13F filings for Q3 2025.